David McNinch is chief business officer at Encoded Therapeutics. He previously served as chief commercial officer of Prothena, Corp., where he led the development of global commercial strategy for its immunotherapy pipeline. Prior to Prothena, he was senior vice president of commercial operations at InterMune, Inc., where he built the commercial organization for successful launch of the first treatment for IPF and eventual acquisition by Roche. Previous roles include various leadership positions of increasing responsibility at Ipsen, Genentech, Novartis, and AstraZeneca. David currently serves as vice chair for the Pulmonary Fibrosis Foundation. He earned his B.S. in marketing from the Darla Moore School of Business at the University of South Carolina.